Introduction
============

The swine major histocompatibility complex (MHC), also referred to as swine leukocyte antigen (SLA), has been associated with the porcine immune response to various infections and vaccinations ([@B20]; [@B19]; [@B22]). SLA has been mapped to pig chromosome 7, and comprises highly polymorphic classical class I, class II, and conservative class III gene clusters ([@B32]). The SLA class I gene cluster contains three constitutively expressed classical genes, *SLA-1, SLA-2*, and *SLA-3*, which are expressed by most cells. The *SLA-1* gene has the highest expression level whereas *SLA-3* has the lowest as a result of different promoter activity ([@B38]). The *SLA-1, SLA-2*, and *SLA-3* genes are highly polymorphic, and 192 alleles (69 *SLA-1*, 87 *SLA-2*, 36 *SLA-3*) have been designated by the SLA Nomenclature Committee of the International Society for Animal Genetics in the Immuno Polymorphism Database (IPD)-MHC SLA sequence database to date^[1](#fn01){ref-type="fn"}^ \[Release 2.2.0.0 (2017-06-01)\] ([@B23]). The extreme polymorphisms of SLA class I genes are concentrated in the α1 and α2 domains, which resemble each other structurally, and together form the class I heavy chain protein peptide-binding groove (PBG). Three-dimensional (3D) crystal structure analysis has indicated that the PBG contains six pockets (A--F), and epitope peptides fixed in the PBG by these pockets. The different allelic forms of SLA class I genes were confirmed to bind different classes of peptide, determined by the fit between the pockets in the PBG of the SLA complex, and the anchor residues in the peptides ([@B42]; [@B4]). SLA class I heavy chain, epitope peptide, and β2-microglobulin (β2m) have also been shown to form a ternary complex, with the protein complexes being expressed constitutively on the surface of virtually all nucleated cells. These are crucially important for the normal growth of CD8+ cytotoxic T lymphocytes (CTLs), and play a pivotal role in the cell-mediated immune response against viral infections and cancer. The protein complexes are mainly involved in the adaptive immune response through their presentation of endogenous epitope peptide antigens to circulating MHC I-restricted CTLs ([@B25]). CTLs kill the specific target cells directly, and also induce host cell-mediated specific immune responses by simultaneously identifying the epitope peptides specifically bound to SLA class I molecules and the SLA class I molecules (MHC restriction). This represents one of the important host-mediated immune-defense responses for controlling virus infection. Furthermore, the protein complexes also interact with natural killer (NK) cells to prevent NK-mediated cytotoxicity ([@B15]).

Pigs are important experimental animals for veterinary and medical studies, including studies of virus infections and pathogenesis, host immunological responses, vaccine evaluation, the identification of T-cell epitopes, and so on. An understanding of peptide binding to SLA class I proteins is therefore of major practical interest. In addition, pigs have an evolutionary resemblance to humans, and share anatomical, physiological, immunological, metabolic, and nutritional similarities, making them promising organ donors for xenotransplantation. The structures of human and mouse MHC class I molecules and their interaction with bound antigenic peptides along with the roles of peptide-interacting pockets in the PBG have been intensively studied. Nevertheless, only a very limited set of the SLA class I molecules have been well documented and reported ([@B42]; [@B4]), and the characteristics of peptide presentation for SLA class I molecules and cellular immune mechanisms have remained elusive until now. The structure and function of SLA class I complexes constructed *in vitro* are currently used to simulate the functions of SLA class I molecules *in vivo* and numerous *in vitro* SLA class I complexes have been constructed and different peptide--SLA-I binding assays have been suggested ([@B27]; [@B37]; [@B8]; [@B30]; [@B42]; [@B7]; [@B4]). A relative simple and rapid, *in vitro* refolding enzyme-linked immunosorbent assay (ELISA)-based method was able to discriminate between peptide-occupied and peptide-free SLA-I complexes based on monoclonal antibody PT85A binding ([@B27]), because the PT85A monoclonal antibody can recognize all SLA class I molecules, from outbred as well as inbred pigs, and the conformational epitope was recognized by PT85A, required the presence of the 'correct' peptide as well as the 'correct' SLA class I molecule sequence ([@B21]; [@B2]; [@B24]). We therefore selected seven SLA-1 molecules identified in Chinese Bama miniature pigs, and one CTL epitope peptide of classical swine fever virus (CSFV) and four epitope peptides of porcine reproductive and respiratory syndrome virus (PRRSV), previously identified by bioinformatics and immunological tests, for the current study. We aimed to construct SLA class I complexes consisting of viral epitope peptides, the extracellular region of the SLA-1 molecules, and β2m using splicing overlap extension polymerase chain reaction (SOE-PCR). The constructed protein complexes were then induced and expressed using an *Escherichia coli* prokaryotic expression system *in vitro*, and the obtained proteins were purified and refolded. Specific binding of SLA-1 proteins to the viral CTL epitope peptides was detected using an ELISA-based method and the MHC restrictions of the five epitope peptides were identified. The SLA-1 molecules selectively binding to an appropriate epitope peptide during antigen presentation were thus characterized *in vitro*. The results of this study will lay the foundations for further studies of cellular immune mechanisms and for the development of effective polypeptide vaccines.

Materials and Methods {#s1}
=====================

Cloning of *SLA-1* Gene
-----------------------

Seven *SLA-1* alleles, including *SLA-1*^∗^0401, 1201, 1301, 11bm01, bm02, 08bm03, and 1101bm05, were obtained from Chinese Bama miniature pigs and submitted to the IPD-MHC database ([@B5]). The SLA Nomenclature Committee currently adopts the naming protocol for human leukocyte antigen alleles, and these alleles have therefore been renumbered as *SLA-1*^∗^04:01:01, 12:01, 13:01, 11:10, 20:01, 08:09, and 11:01:02, respectively, in the IPD-MHC database \[Release 2.1.0.3 (2017-01-25)\]. The seven alleles were cloned into the pMD 18-T vector (TaKaRa, Dalian, China) and the recombinant plasmids pMD18-T-SLA-1^∗^X (where X indicates 04:01:01, 12:01, 13:01, 11:10, 20:01, 08:09, or 11:01:02 allele) were collected for further study.

Construction of Recombinant pET-SLA-1^∗^X-β2m and pET-Epitope-SLA-1^∗^X-β2m Expression System
---------------------------------------------------------------------------------------------

Seven *SLA-1* gene fragments encoding the extracellular domains (α1, α2, and α3 domains) were amplified from the plasmids pMD18-T-SLA-1^∗^X using primers P1aF/P1bF and P2R, respectively (**Table [1](#T1){ref-type="table"}**). The swine *β2m* gene (complete mature β2m, omitting leader peptide) was amplified from cDNA from peripheral blood mononuclear cells of Chinese Bama miniature pig using primers P3F and P4R (**Table [1](#T1){ref-type="table"}**). PCR amplifications were performed using KOD-Plus-Neo DNA polymerase system (Toyobo, Japan) according to the manufacturer's instructions. The amplified *SLA-1*^∗^04:01:01 allele fragment and *β2m* gene were linked with a glycine-rich linker gene consisting of 15 amino acids (G4S)3 using the SOE-PCR method ([@B8]) (**Figure [1](#F1){ref-type="fig"}**). The SOE-PCR product was purified, ligated to the pMD18-T vector (TaKaRa), and sequenced. The verified fusion gene, named pMD18-T-SLA-1^∗^040101-β2m, was used as template to construct the remaining six recombinant genes, pMD18-T-SLA-1^∗^X-β2m, through restriction digestion with *Eco*R I and *Xho* I, ligation, and sequencing. The seven pMD18-T-SLA-1^∗^X-β2m fusion genes were then digested with *Nde* I and *Not* I and cloned into the pET-30a(+) prokaryotic expression vector at the *Nde* I and *Not* I restriction sites to create pET-SLA-1^∗^X-β2m.

###### 

Splicing overlap extension PCR primers.

  Name   Primer sequence (5′-3′)^a^                                                      Amplified gene                            Comments
  ------ ------------------------------------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------
  P1aF   CGC **CATATG GAATTC** GGTCCCCACTCCCTGAGCTATTTC                                  04:01:01, 12:01, 13:01, 20:01, 11:01:02   Extracellular part of SLA-1, amino acids 22--295 (exons 2, 3, and 4).
  P1bF   TCA **CATATG GAATTC** GGTCCCCACTCCCTGAGGTATTTC                                  11:10, 08:09                              
  P2R    [ACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCACC]{.ul} **CTCGAG** CCATCTCAGGGTGAGGGGCTCC   All *SLA-1* alleles                       
  P3F    [GGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCG]{.ul} GTCGCGCGTCCCCCGAAGGTTC              *β*2m gene                                Swine *β2m* gene (GenBank accession number NM213978), amino acids 21--118.
  P4R    TT **GCGGCCGC** GTGGTCTCGATCCCACTTAACTATC                                                                                 

a

Underlined part denotes a glycine-rich linker gene (G4S)3. Bold letters indicate restriction enzymes sites.

![Construction of the pET-SLA-1^∗^X-β2m and pET-epitope-SLA-1^∗^X-β2m expression system. Horizontal boxes represent the amplified *SLA-1*^∗^X gene and *β2m* gene sequence, the glycine-rich linker gene sequence, the C-terminal His-tag sequence derived from the pET-30a(+) prokaryotic expression vector, and viral CTL epitope peptide sequence. Upper case letters outside boxes indicate amino acids. Bold letters indicate restriction enzymes sites. Arc represents the pET-30a(+) vector.](fmicb-08-02524-g001){#F1}

One CTL epitope peptide of the CSFV non-structural protein 4A (NS4A) and four CTL epitope peptides of PRRSV glycoproteins 4 (GP4) and 5 (GP5), and the nucleocapsid protein (N), previously identified by bioinformatics and immunological tests ([@B28]; [@B39]; [@B3]), were selected to identify their MHC restriction. Double-stranded protein constructs consisting of selected viral CTL epitope peptides linked to the SLA-1 and β2m were constructed from single-stranded nucleotide sequences encoding the epitope peptides and the glycine-rich linker with *Nde* I and *Eco*R I compatible overhang (**Table [2](#T2){ref-type="table"}**). The double-stranded nucleotides were generated by mixing equal amounts of each plus-sense and minus-sense nucleotide, heating to 95°C for 5 min, annealing at 37°C for 1 h, and cooling slowly to room temperature. The double-stranded constructs were digested with *Nde* I and *Eco*R I and ligated to pET-SLA-1^∗^X-β2m at the *Nde* I and *Eco*R I restriction sites, named pET-epitope-SLA-1^∗^X-β2m ('epitope' indicates the five selected viral CTL epitope peptides, respectively), as shown in **Figure [1](#F1){ref-type="fig"}**. All recombinant plasmids were verified by sequencing and restriction digestion and transfected into *E. coli* Rosetta (DE3).

###### 

Nucleotides encoding viral CTL epitope peptides and the glycine-rich linker gene.

  Virus   Protein   Sequence (5′-3′)^a^                                                                                Reference
  ------- --------- -------------------------------------------------------------------------------------------------- -----------
                            E N A L L V A L F                                                                          
  CSFV    NS4A      NS4A-P: **TATG** GAA AAC GCT CTG CTG GTT GCT CTG TTC [GGTGGCGGTTCCGGCGGTGGCTCCGGCGGT]{.ul} **G**   [@B28]
                    NS4A-M: **AATTC** [ACCGCCGGAGCCACCGCCGGAACCGCCACC]{.ul} GAACAGAGCAACCAGCAGAGCGTTTTC **CA**         
                            C L F A I L L A I                                                                          
  PRRSV   GP4       GP4-5P: **TATG** TGT CTT TTT GCC ATC CTA CTG GCA ATT [GGTGGCGGTTCCGGCGGTGGCTCCGGCGGT]{.ul} **G**   [@B3]
                    GP4-5M: **AATTC** [ACCGCCGGAGCCACCGCCGGAACCGCCACC]{.ul} AATTGCCAGTAGGATGGCAAAAAGACA **CA**         
                            N P E K P H F P L                                                                          
          N         N-15P: **TATG** AAC CCG GAG AAG CCC CAT TTC CCT CTA [GGTGGCGGTTCCGGCGGTGGCTCCGGCGGT]{.ul} **G**    
                    N-15M: **AATTC** [ACCGCCGGAGCCACCGCCGGAACCGCCACC]{.ul} TAGAGGGAAATGGGGCTTCTCCGGGTT **CA**          
                            F S L P T Q H T V                                                                          
                    N-6P: **TATG** TTT AGT TTG CCG ACG CAA CAT ACT GTG [GGTGGCGGTTCCGGCGGTGGCTCCGGCGGT]{.ul} **G**     
                    N-6M: **AATTC** [ACCGCCGGAGCCACCGCCGGAACCGCCACC]{.ul} CACAGTATGTTGCGTCGGCAAACTAAA **CA**           
                            L A A L I C F V I R L A K N C                                                              
          GP5       G9-P: **TATG** CTG GCT GCG CTG ATT TGC TTT GTC ATT AGG CTT GCG AAG AAC TGC                         [@B39]
                    [GGTGGCGGTTCCGGCGGTGGCTCCGGCGGT]{.ul} **G**                                                        
                    G9-M: **AATTC** [ACCGCCGGAGCCACCGCCGGAACCGCCACC]{.ul} GCAGTTCTTCGCAAGCCTAATGACAAAGC                
                    AAATCAGCGCAGCCAG **CA**                                                                            

a

P and M indicate plus-sense and minus-sense sequences, respectively. Bold letters represent the sequences sticky to the ends of

Nde

I and

Eco

R I, respectively. Underlined part denotes the glycine-rich linker gene (

Figure

1

). The amino acid sequences of viral CTL epitope peptides are given above the plus-sense sequences.

Protein Expression, Sodium Dodecyl Sulfate--Polyacrylamide Gel Electrophoresis (SDS--PAGE), Refolding, and Western Blotting
---------------------------------------------------------------------------------------------------------------------------

Protein expression was performed as described previously ([@B18]). The harvested bacterial pellets were saved at -80°C for at most one day. Samples were analyzed by SDS-PAGE before and after induction with isopropyl β-[D]{.smallcaps}-1-thiogalactopyranoside (IPTG). All the recombinant proteins were present as insoluble inclusion bodies. Refolding of the recombinant protein in inclusion body form was carried out using a protein refolding kit (70123-3, Merck-Millipore, Germany) according to the manufacturer's protocol. The refolded protein bands were electrotransferred onto polyvinylidene difluoride membranes and subjected to western blot analysis. The membrane was blocked overnight at 4°C with phosphate-buffered saline (PBS) containing 5% skim milk, incubated for 1 h at 37°C with 1:3000 diluted monoclonal anti-polyHistidine antibody (Sigma--Aldrich, United States), and washed three times for 5 min each with PBS containing 0.05% Tween 20 (PBST). The membrane was then incubated for 1 h at 37°C with horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) antibody (Sigma--Aldrich) diluted at 1:10,000, and washed again three times. Proteins were visualized using 3,3′-diaminobenzidine/H~2~O~2~.

Specific Binding of Viral CTL Epitope Peptides to SLA-1 Proteins
----------------------------------------------------------------

The specific binding of SLA-1 to viral CTL epitope peptides was analyzed using an ELISA-based method, as described previously ([@B27]). Briefly, 100 μl of PBS containing 7.2 μg refolded protein was added to a single well of nickel-coated plates (Pierce, Thermo Fisher, United States) and used to capture the specific recombinant protein. The plates were shaken overnight at room temperature and washed three times with PBST for 5 min each. Monoclonal antibody PT85A (100 μl) (Monoclonal Antibody Center, Washington State University, United States) diluted 1:200 in 1% bovine serum albumin was then added to each well and the plates were incubated for 1 h at 37°C. Following washing, 100 μl/well of horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) antibody (Sigma--Aldrich) diluted 1:10,000 in 1% bovine serum albumin was added and the plates were incubated for 1 h at 37°C. Finally, the plates were washed and developed for 20 min at room temperature with TMB (Sigma--Aldrich). The optical density (OD) was read at 450 nm using a standard microplate reader. Recombinant pET-SLA-1^∗^X-β2m protein was used as a negative control. The specific binding of SLA-1 proteins to viral CTL epitope peptides was determined by a relative OD values ≥ 2, calculated as OD (pET-epitope-SLA-1^∗^X-β2m)/OD (pET-SLA-1^∗^X-β2m). Each sample was assayed in triplicate to determine the mean value.

Amino Acid Alignment of α1 and α2 Domains and PBG Comparison of SLA-1^∗^04:01:01 and SLA-1^∗^13:01 Molecules
------------------------------------------------------------------------------------------------------------

The amino acid sequences of the α1 and α2 domains of the SLA-1 were compared using the search similarity and multiple alignment programs of the Lasergene package (DNASTAR, Madison, WI, United States). The crystal structure of the SLA-1^∗^04:01:01 molecule was obtained from the Protein Data Bank, with accession number [3QQ4](3QQ4) ([@B42]). The 3D structure of the SLA-1^∗^13:01 molecule was modeled using SWISS-MODEL program^[2](#fn02){ref-type="fn"}^. All 3D structures were drawn using Chimera software^[3](#fn03){ref-type="fn"}^.

Specific Binding of CSFV NS4A Epitope Peptide to Mutant SLA-1^∗^04:01:01 and SLA-1^∗^13:01 Molecules
----------------------------------------------------------------------------------------------------

We investigated the functions of the amino acids located in the pockets of the PBG in the α1 and α2 domains of the SLA-1^∗^04:01:01 and SLA-1^∗^13:01 by mutating the amino acid residues of one molecule to the corresponding amino acid residues of the other molecule by site-directed mutagenesis, using overlap PCR. The primers used for mutation of the SLA-1^∗^04:01:01 and SLA-1^∗^13:01 are listed in **Table [3](#T3){ref-type="table"}**. pET-NS4A-SLA-1^∗^040101-β2m and pET-NS4A-SLA-1^∗^1301-β2m plasmids were used as templates, respectively. The SOE-PCR primers were 5′-CGC [CAT ATG]{.ul} GAA AAC GCT CTG CTG GTT GCT CTG-3′, and 5′-TT[G CGG CCG C]{.ul}GT GGT CTC GAT CCC ACT TAA CTA TC-3′ (underlined letters denote *Nde* I and *Not* I restriction sites, respectively). The resulting products were purified and digested with *Nde* I and *Not* I and ligated to the pET-30a(+) vector at the *Nde* I and *Not* I restriction sites. All mutant plasmids were verified by sequencing and restriction digestion and expressed in *E. coli* Rosetta (DE3). Mutant proteins were expressed in inclusion bodies and further refolded, as described above. Specific binding of the CSFV NS4A epitope peptide to the mutant SLA-1^∗^04:01:01 and SLA-1^∗^13:01 proteins was analyzed using an ELISA-based method, as described previously ([@B27]). In order to better analyze the strength of peptides binding to SLA-1^∗^04:01:01, SLA-1^∗^13:01 and their mutants, the relative levels of CSFV NS4A epitope peptide binding to SLA-1^∗^04:01:01, SLA-1^∗^13:01, and their mutant molecules were compared. Briefly, the relative level (strength) of SLA-1^∗^13:01 molecule binding to epitope peptide was designated as 100% and the strength of peptide binding to other SLA-1 molecules were showed by the ratio of their relative OD values compared with SLA-1^∗^13:01.

###### 

Overlap PCR primers used for mutation of SLA-1^∗^04:01:01 and SLA-1^∗^13:01 molecules.

  Molecule           Name                Primer sequence (5′-3′)^a^            Mutant amino acid   Mutant molecule name
  ------------------ ------------------- ------------------------------------- ------------------- --------------------------
  SLA-1^∗^04:01:01   04:01:01/66F        ATCGGGAGACGCGG**AAA**GTCAAGGAAAC      66 (N→K)            SLA-1^∗^04:01:01/66
                     04:01:01/66R        GTTTCCTTGAC**TTT**CCGCGTCTCCCGAT                          
                     04:01:01/70F        AATGTCAAGGAA**AAC**GCACAGACTTAC       70 (T→N)            SLA-1^∗^04:01:01/70
                     04:01:01/70R        GTAAGTCTGTGC**GTT**TTCCTTGACATT                           
                     04:01:01/99F        TCCAGAGCATG**TTT**GGCTGCTACTTGGGA     99 (Y→F)            SLA-1^∗^04:01:01/99
                     04:01:01/99R        TCCCAAGTAGCAGCC**AAA**CATGCTCTGGA                         
                     04:01:01/151F       TGGGAGGCGGCC**AAT**GAGGCGGAGCGTAGGA   151 (D→N)           SLA-1^∗^04:01:01/151
                     04:01:01/151R       TCCTACGCTCCGCCTC**ATT**GGCCGCCTCCCA                       
                     04:01:01/152F       GGCCGAT**GTG**GCGGAGCGTAGGAGGAGCTA    152 (E→V)           SLA-1^∗^04:01:01/152
                     04:01:01/152R       TAGCTCCTCCTACGCTCCGC**CAC**ATCGGCC                        
                     04:01:01/151/152F   TGGGAGGCGGCC**AATGTG**GCGGAGCGTAGGA   151-152 (DE→NV)     SLA-1^∗^04:01:01/151/152
                     04:01:01/151/152R   TCCTACGCTCCGC**CACATT**GGCCGCCTCCCA                       
  SLA-1^∗^13:01      13:01/66F           ATGAGGAGACGCGG**AAT**GTCAAGGACAA      66 (K→N)            SLA-1^∗^13:01/66
                     13:01/66R           TTGTCCTTGAC**ATT**CCGCGTCTCCTCAT                          
                     13:01/70F           AAAGTCAAGGAC**ACC**GCACAGACTTAC       70 (N→T)            SLA-1^∗^13:01/70
                     13:01/70R           GTAAGTCTGTGC**GGT**GTCCTTGACTTT                           
                     13:01/99F           TCCAGAGCATG**TAC**GGCTGCTACTTGGGA     99 (F→Y)            SLA-1^∗^13:01/99
                     13:01/99R           TCCCAAGTAGCAGCC**GTA**CATGCTCTGGA                         
                     13:01/151F          TGGGAGGCGGCC**GAT**GTGGCGGAGCGTAGGA   151 (N→D)           SLA-1^∗^13:01/151
                     13:01/151R          TCCTACGCTCCGCCAC**ATC**GGCCGCCTCCCA                       
                     13:01/152F          GGCCAAT**GAG**GCGGAGCGTAGGAGGAGCTA    152 (V→E)           SLA-1^∗^13:01/152
                     13:01/152R          TAGCTCCTCCTACGCTCCGC**CTC**ATTGGCC                        
                     13:01/151/152F      TGGGAGGCGGCC**GATGAG**GCGGAGCGTAGGA   151-152 (NV→DE)     SLA-1^∗^13:01/151/152
                     13:01/151/152R      TCCTACGCTCCGC**CTCATC**GGCCGCCTCCCA                       

a

Letters in boldface type represent mutated nucleotides, which changed the corresponding amino acids.

Specific Binding of PRRSV Epitope Peptides to SLA-1^∗^04:01:01/151/152 and SLA-1^∗^13:01/151/152 Mutant Proteins
----------------------------------------------------------------------------------------------------------------

Double-stranded nucleotides of the four PRRSV epitope peptides were made by mixing equal amounts of the plus-sense and minus-sense nucleotides (**Table [2](#T2){ref-type="table"}**), heating to 95°C for 5 min, annealing at 37°C for 1 h, and cooling slowly to room temperature. The double-stranded constructs were digested with *Nde* I and *Eco*R I and ligated to pET-SLA-1^∗^040101/151/152-β2m and pET-SLA-1^∗^1301/151/152-β2m at the *Nde* I and *Eco*R I restriction sites, respectively. Similarly, the recombinant proteins were expressed in inclusion bodies and further refolded, as described above. The specific binding of the four PRRSV epitope peptides to SLA-1^∗^04:01:01/151/152 and SLA-1^∗^13:01/151/152 was analyzed using an ELISA-based method, as described previously ([@B27]).

Results
=======

Construction of pET-SLA-1^∗^X-β2m and pET-Epitope-SLA-1^∗^X-β2m Expression Systems
----------------------------------------------------------------------------------

The extracellular part of seven SLA-1 molecules and the mature peptide part of the *β2m* gene were successfully amplified to single fragments of 879 and 340 bp, respectively. The sequences were identical to the previously published sequences ([@B26]; [@B5]). The SLA-1^∗^X-β2m fusion genes were obtained using the P1a/P1b and P4R primers. Agarose gel electrophoresis revealed a specific band at about 1200 bp, in accordance with the expected size of 1192 bp. The pET-SLA-1^∗^X-β2m expression systems were constructed as illustrated in **Figure [1](#F1){ref-type="fig"}**. The structures of the plasmids were confirmed by digestion with *Nde* I and *Not* I, followed by sequencing. The sequencing results showed that the inserted genes were 1192 bp in length, and identical to the extracellular sequences of SLA-1 and the mature peptide sequence of the *β2m* gene described above, with an insertion encoding a 15-amino acid glycine-rich linker. Similar results were found for the pET-epitope-SLA-1^∗^X-β2m expression systems (**Figure [1](#F1){ref-type="fig"}**). The inserted genes were 1249 bp (NS4A, GP4-5, N-15, and N-6 epitope peptides) and 1267 bp (G9 epitope peptide) in length, and identical to the epitope peptide sequences and SLA-1^∗^X-β2m fusion gene sequences, with an insertion encoding a 10 amino acid glycine-rich linker.

Expression, SDS--PAGE, and Western Blotting
-------------------------------------------

A total of 42 different recombinant proteins were expressed from the pET-30a(+) vector in *E. coli* Rosetta, including seven pET-SLA-1^∗^X-β2m proteins and 35 pET-epitope-SLA-1^∗^X-β2m proteins ('epitope' indicates NS4A, GP4-5, N-15, N-6, or G9 epitope peptide, X indicates 04:01:01, 12:01, 13:01, 11:10, 20:01, 08:09, or 11:01:02 molecule). All recombinant protein products were inducible with 1 mmol/L IPTG, and were not produced in non-induced cultures (**Figure [2](#F2){ref-type="fig"}**, lane 3). For example, SDS-PAGE showed that the transformed cells with pET-SLA-1^∗^040101-β2m produced a large amount of a protein with a mass of about 45 kDa (**Figure [2](#F2){ref-type="fig"}**, lane 2), and analysis of pET-NS4A-SLA-1^∗^040101-β2m showed protein expression at a position equivalent to a mass of about 47 kDa (**Figure [2](#F2){ref-type="fig"}**, lane 1). Similar results were found for the other recombinant proteins. Solubility analysis showed that all the recombinant proteins were present as insoluble inclusion bodies. Effective inclusion body purification and protein refolding produced activated protein preparations of adequate purity (**Figure [2](#F2){ref-type="fig"}**, lane 4 and 5). Western blotting with an anti-His tag monoclonal antibody showed that the vector-encoded C-terminal His-tag was present in all the recombinant proteins (**Figure [2](#F2){ref-type="fig"}**, lane 6 and 7).

![Analysis of inclusion body proteins by SDS-PAGE and western blotting. M: protein marker; lanes 1 and 2: pET-NS4A-SLA-1^∗^040101-β2m and pET-SLA-1^∗^040101-β2m proteins after induction with IPTG in *E. coli* Rosetta; lane 3: pET-NS4A-SLA-1^∗^040101-β2m protein before induction with IPTG; lanes 4 and 5: purified and refolded pET-NS4A-SLA-1^∗^040101-β2m and pET-SLA-1^∗^040101-β2m proteins; lanes 6 and 7: pET-NS4A-SLA-1^∗^040101-β2m and pET-SLA-1^∗^040101-β2m proteins visualized by western blotting. Arrows indicate expected position of recombinant proteins.](fmicb-08-02524-g002){#F2}

Detection of Specific Binding of Viral CTL Epitope Peptides to SLA-1 Proteins
-----------------------------------------------------------------------------

The results of detection using the ELISA-based method are illustrated in **Figure [3](#F3){ref-type="fig"}** (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). SLA-1^∗^13:01, SLA-1^∗^11:10, and SLA-1^∗^11:01:02 bound specifically to different CTL epitopes of CSFV and PRRSV, and the MHC restrictions of the five epitopes were identified. For example, the pET-NS4A-SLA-1^∗^13:01-β2m protein exhibited 4.7-fold higher reactivity than pET-SLA-1^∗^13:01-β2m, and the relative OD values for the other SLA-1 were \< 2.0 (**Figure [3A](#F3){ref-type="fig"}**). This demonstrated that there was specific binding of the CSFV NS4A epitope peptide to the SLA-1^∗^13:01; i.e., the CSFV NS4A (ENALLVALF) peptide was a SLA-1^∗^13:01-restricted CTL epitope. Similarly, the PRRSV N-15 (NPEKPHFPL) peptide was a SLA-1^∗^13:01-restricted CTL epitope (**Figure [3C](#F3){ref-type="fig"}**). The MHC restrictions of PRRSV GP4-5 (CLFAILLAI) and N-6 (FSLPTQHTV) epitopes were identical, and they could bind specifically to SLA-1^∗^13:01, SLA-1^∗^11:10, and SLA-1^∗^11:01:02 (**Figures [3B,D](#F3){ref-type="fig"}**). The PRRSV G9 (LAALICFVIRLAKNC) peptide bound specifically to SLA-1^∗^13:01 and SLA-1^∗^11:10 and was thus a SLA-1^∗^13:01- and SLA-1^∗^11:10-restricted CTL epitope (**Figure [3E](#F3){ref-type="fig"}**).

![Specific binding of viral CTL epitope peptides to SLA-1 proteins. Specific binding of SLA-1 to viral CTL epitope peptides was determined by a relative OD value ≥ 2. Each sample was assayed in triplicate to determine the mean value. **(A)** Specific binding of seven SLA-1 proteins to CSFV NS4A epitope peptide. **(B)** Specific binding of seven SLA-1 proteins to PRRSV GP4-5 epitope peptide. **(C)** Specific binding of seven SLA-1 proteins to PRRSV N-15 epitope peptide. **(D)** Specific binding of seven SLA-1 proteins to PRRSV N-6 epitope peptide. **(E)** Specific binding of seven SLA-1 proteins to PRRSV G9 epitope peptide.](fmicb-08-02524-g003){#F3}

Amino Acid Sequence Analysis and PBG Comparison
-----------------------------------------------

Analysis of the amino acid sequence homologies of the α1 and α2 domains among the seven SLA-1 molecules showed the highest homology between SLA-1^∗^04:01:01 and SLA-1^∗^13:01, of up to 97.1% (**Figure [4A](#F4){ref-type="fig"}**). Alignment of the amino acid sequences of the α1 and α2 domains showed that only eight amino acid residues, 58(E/D), 62(R/E), 66(N/K), 69(E/D), 70(T/N), 99(Y/F), 151(D/N), and 152(E/V), were discrepant between the SLA-1^∗^04:01:01 and SLA-1^∗^13:01 molecules (**Figure [4B](#F4){ref-type="fig"}**). The 3D structure of the SLA-1^∗^13:01 molecule was modeled using the SWISS-MODEL program based on the crystal structure of the SLA-1^∗^04:01:01 molecule ([@B42]), and the PBGs of SLA-1^∗^04:01:01 and SLA-1^∗^13:01 were compared. Four discrepant residues were involved in constituting six pockets of the PBG: pocket B \[66(N/K)\], pocket C \[70(T/N)\], pocket D \[99(Y/F)\], and pocket E \[152(E/V)\] (**Figure [5](#F5){ref-type="fig"}**). The other four discrepant residues might play roles in the support, stability, and connection of the six pockets.

![Amino acid sequence homology of α1 and α2 domains among seven SLA-1 molecules **(A)** and amino acid alignment of α1 and α2 domains between SLA-1^∗^04:01:01 and SLA-1^∗^13:01 molecules **(B)**. Numbers above the line indicate the amino acid sequence numbers of each sequence counted from the α1 domain of the SLA-1 molecule. Dots indicate identical amino acids compared with the SLA-1 molecules common consensus sequence.](fmicb-08-02524-g004){#F4}

![Structural alignments of the PBG of SLA-1^∗^04:01:01 and SLA-1^∗^13:01 molecules. **(A)** 3D models of SLA-1^∗^04:01:01 (PDB code: 3QQ4) and SLA-1^∗^13:01 built by the SWISS-MODEL program. The PBG is shown in pink. Eight discrepant amino acid residues are indicated by different colors in the stick model. **(B)** Superimposition of SLA-1^∗^04:01:01 and SLA-1^∗^13:01 PBG structures showing conformational variation in Asp^151^Glu^152^ and Asn^151^Val^152^. SLA-1^∗^04:01:01 is shown in light brown and SLA-1^∗^13:01 in cyan. The stick models and surfaces of residues at positions 151 and 152 are shown in green and red, respectively.](fmicb-08-02524-g005){#F5}

Detection of Specific Binding of CSFV NS4A Epitope Peptide to Mutant SLA-1^∗^04:01:01 and SLA-1^∗^13:01 Proteins
----------------------------------------------------------------------------------------------------------------

SLA-1^∗^04:01:01 and SLA-1^∗^13:01 molecules showed high amino acid sequence homology (97.1%) in the α1 and α2 domains, but exhibited different binding specificities to viral epitopes (**Figure [3](#F3){ref-type="fig"}**). We therefore mutated four discrepant residues in one molecule, 66(N/K), 70(T/N), 99(Y/F), and 152(E/V), respectively, to the corresponding residues of the other molecule and analyzed the effects on their binding specificity to the CSFV NS4A epitope peptide (**Supplementary Table [S2](#SM2){ref-type="supplementary-material"}**). The relative OD values were \> 2.0 when the Lys^66^, Asn^70^, and Phe^99^ residues of the SLA-1^∗^13:01 were mutated, respectively (**Figure [6A](#F6){ref-type="fig"}**). SLA-1^∗^13:01/66, SLA-1^∗^13:01/70, and SLA-1^∗^13:01/99 mutant proteins retained specific binding to the CSFV NS4A epitope peptide, but specific binding was lost in the SLA-1^∗^13:01/152 mutant protein with a mutated Val^152^ residue. In the case of the SLA-1^∗^04:01:01, the NS4A epitope peptide could not bind to any of the four mutant proteins in which the Asn^66^, Thr^70^, Tyr^99^, or Glu^152^ residue was mutated to the corresponding amino acid residue of the SLA-1^∗^13:01 (**Figure [6A](#F6){ref-type="fig"}**). Similar situations were found when the 151(D/N) residue of one molecule was mutated to the corresponding amino acid residue of the other molecule. However, when the 151(D/N) and 152(E/V) residues of SLA-1^∗^13:01 and SLA-1^∗^04:01:01 were mutated simultaneously, the NS4A epitope peptide could still bind to the SLA-1^∗^04:01:01/151/152 mutant protein, but not to the SLA-1^∗^13:01/151/152 mutant protein (**Figure [6A](#F6){ref-type="fig"}**). In addition, the binding strength of NS4A peptide to SLA-1^∗^13:01 molecule were decreased at different degrees when mutating these amino acid residues to the corresponding residues of SLA-1^∗^04:01. However, the binding strength of NS4A peptide to SLA-1^∗^04:01:01/151/152 mutant was obviously increased compared with SLA-1^∗^04:01:01 and was slightly lower than SLA-1^∗^13:01 (**Figure [6B](#F6){ref-type="fig"}**).

![Specific binding of CSFV NS4A epitope peptide to mutant SLA-1^∗^04:01:01 and SLA-1^∗^13:01 proteins. **(A)** Detection of specific binding of NS4A peptide to mutant SLA-1^∗^04:01:01 and SLA-1^∗^13:01 proteins. Specific binding of the mutant SLA-1 proteins to the epitope peptide were determined by a relative OD value ≥ 2. Columns of the same pattern indicate the results of NS4A epitope peptide-specific binding to SLA-1^∗^04:01:01 and SLA-1^∗^13:01 proteins with mutated residues at the same position, respectively. **(B)** The binding strength of NS4A peptide to mutant SLA-1^∗^04:01:01 and SLA-1^∗^13:01 proteins. The relative level (strength) of SLA-1^∗^13:01 molecule binding to epitope peptide was designated as 100% and the strength of peptide binding to other SLA-1 molecules were showed by the ratio of their relative OD values compared with SLA-1^∗^13:01.](fmicb-08-02524-g006){#F6}

Detection of Specific Binding of PRRSV Epitope Peptides to SLA-1^∗^04:01:01/151/152 and SLA-1^∗^13:01/151/152 Mutant Proteins
-----------------------------------------------------------------------------------------------------------------------------

The specific binding of the four PRRSV epitope peptides (GP4-5, N-15, N-6, and G9) to the SLA-1^∗^04:01:01/151/152 and SLA-1^∗^13:01/151/152 mutant proteins are shown in **Figure [7](#F7){ref-type="fig"}** (**Supplementary Table [S3](#SM3){ref-type="supplementary-material"}**). Similar to the results for the CSFV NS4A epitope peptide, the PRRSV GP4-5, N-15, N-6, and G9 epitope peptides could bind specifically to the SLA-1^∗^04:01:01/151/152 mutant protein, but not to the SLA-1^∗^13:01/151/152 mutant protein. Similarly, the binding strength of SLA-1^∗^04:01:01/151/152 mutant to the four epitope peptides had obvious increasing compared with SLA-1^∗^04:01:01 and was slightly lower than SLA-1^∗^13:01 except GP4-5 peptide. In turn, the binding strength of SLA-1^∗^13:01/151/152 mutant to four epitope peptides were nearly identical to SLA-1^∗^04:01:01. We therefore speculated that the fixed combination of amino acid residues at positions 151 and 152 (Asn^151^Val^152^) might be the key residues affecting the binding of viral CTL epitope peptides to SLA-1^∗^13:01 and SLA-1^∗^04:01:01. Structural alignment of the PBGs of SLA-1^∗^13:01 and SLA-1^∗^04:01:01 revealed that pocket E was larger in SLA-1^∗^13:01 than in SLA-1^∗^04:01:01 as a result of different surfaces of the concave Val^152^ and salient Glu^152^ residues (**Figure [5A](#F5){ref-type="fig"}**). Simultaneously, the Asn^151^ residue of SLA-1^∗^13:01 occurred in turn and random coil content and presented more flexibility than Asp^151^ of SLA-1^∗^04:01:01 to support pocket E (**Figure [5B](#F5){ref-type="fig"}**). Pocket E in the SLA-1^∗^13:01 protein might thus have fewer steric limitations and be able to accommodate more residues of viral CTL epitope peptides.

![Specific binding of five viral epitope peptides to SLA-1^∗^04:01:01/151/152 and SLA-1^∗^13:01/151/152 mutant proteins. **(A)** Detection of specific binding of five viral epitope peptides to SLA-1^∗^13:01 when the residues at positions 151 and 152 were simultaneously mutated to the corresponding amino acid residues of the SLA-1^∗^04:01:01. **(B)** Detection of specific binding of five viral epitope peptides to SLA-1^∗^04:01:01 when residues at positions 151 and 152 were simultaneously mutated to the corresponding amino acid residues of the SLA-1^∗^13:01. **(C)** The binding strength of five viral epitope peptides to SLA-1^∗^04:01:01/151/152 and SLA-1^∗^13:01/151/152 mutant proteins. The relative levels (strength) of SLA-1^∗^13:01 molecule binding to epitope peptide were designated as 100% and the strength of peptide binding to other SLA-1 molecules were showed by the ratio of their relative OD values compared with SLA-1^∗^13:01.](fmicb-08-02524-g007){#F7}

Discussion
==========

Three constitutively expressed and highly polymorphic classical SLA class I genes map to the SLA complex, *SLA-1, SLA-2*, and *SLA-3* ([@B32]). SLA class I molecules play a crucial role in cellular immune antigen presentation in pigs and in xenotransplantation of pig organs into humans. The *SLA-1* gene has the highest expression level ([@B38]), implying that SLA-1 molecules might play a dominant role in the immune process, including presentation of CTL epitopes. Sixty-nine *SLA-1* alleles, identified in various pig breeds and cell lines ([@B34]; [@B16], [@B17]; [@B13], [@B11], [@B12]; [@B5], [@B6]), have been deposited in the IPD-MHC SLA sequence database to date, and this number is increasing as more efficient SLA-typing techniques are employed and more experimental pig breeds are developed worldwide. Polymorphism of SLA class I molecules is concentrated in the region of the PBG, and determines the distinct structure of the PBG. The structural basis of swine CTL epitope presentation has been illustrated by determination of the crystal structure of SLA-1^∗^04:01:01 with a peptide from swine influenza A virus and Ebola virus ([@B42]). The PBG was shown to be classified into six pockets, A--F, which determined the peptide-binding specificity. The binding of different SLA molecules to different classes of peptides was determined by the fit between these pockets and the anchor residues in the peptides ([@B42]; [@B4]). Viral peptides interact with the pockets to form a heterotrimeric complex, including SLA class I heavy chain, the epitope peptide, and β2m. In the initial stage of virus infection, antigenic proteins are processed in a proteasome-dependent or -independent manner, and the resultant short peptides are then transported to the endoplasmic reticulum and loaded onto the PBG of SLA class I molecules. The peptide-loaded SLA class I complexes are then translocated to the cell surface and recognized by CTLs with specific T-cell receptors ([@B33]; [@B41]). This immune recognition induces an MHC-restricted CD8+ T-cell response characterized by the proliferation of CTLs, prevention of pathogen release, lysis of the virally infected cells, and killing and elimination of the infected cells by host effector T cells ([@B25]). Identification of epitope peptide binding to SLA class I molecules represents a critical step in this process. Moreover, viral epitopes bind to the PBG with different specificities, in an MHC-restricted manner. It is therefore essential to characterize the binding of SLA class I molecules to viral CTL epitope peptides because of the significance of this process for monitoring CD8+ T cell immune responses and understanding the mechanisms of cellular immunity.

Historically, the peptide-binding specificity of SLA class I molecules has been characterized by various methods, each with particular advantages and drawbacks ([@B27]; [@B33]; [@B37]; [@B8]; [@B30]; [@B42]; [@B29], [@B31]). The refolding of the MHC class I complex is known to be influenced by the presence or absence of a peptide ([@B9]). The refolding and conformation of the SLA class I complex depends on whether the epitope peptide can bind to the SLA class I molecules. Epitope has generally been reported to be required for *in vitro* refolding of SLA class I molecules ([@B9]). The refolding and conformational differences can be assessed using the monoclonal antibody PT85A, and differences in binding reactivities between epitope peptides and SLA-1 molecules can then be reflected by the relative OD values following ELISA. In this study, we used a rapid and simple *in vitro* refolding assay ([@B27]) to examine the specific binding of seven SLA-1 proteins to five viral CTL epitope peptides, previously identified using bioinformatics and immunological tests ([@B28]; [@B39]; [@B3]), but with unknown MHC restriction. Although the CSFV NS4A epitope peptide (ENALLVALF) has been described as a SLA d/d haplotype (H4/H4 haplotype: *SLA-1*^∗^04:01:01-*SLA-2*^∗^04:01-*SLA-3*^∗^04:01)-restricted CD8+ T cell epitope ([@B28]), it was unknown to which of these three class I genes it was restricted. The current results showed that SLA-1^∗^13:01, SLA-1^∗^11:10, and SLA-1^∗^11:01:02 proteins were able to bind specifically to different CTL epitopes of CSFV and PRRSV. This suggests that the compatibilities of the pockets in the PBG of SLA class I molecules are distinct, and that a broad range of protective CD8+ T cell responses could potentially be elicited, associated with the various peptide conformations. The distinct peptide conformations mainly result from the flexible side chains of the pockets, and do not involve the α-helixes and β-sheets that form the PBG. The fact that different SLA-1 can bind to the same CTL epitope indicates that the same peptide could be presented by different SLA class I molecules, with chemical specificity determined by different preferences for certain anchor residues. Many *SLA-1* suballeles could also show similar anchor residue preference due to the presence of identical key residues in pockets ([@B36]). Many studies have also shown that water molecules, platform adjustment, or the presence of only one flexible pocket can contribute to the accommodation of different peptides ([@B35]; [@B36]; [@B14]). Furthermore, although the conformations of one SLA-1 pockets are unique, similar pockets were could found in other SLA-1 molecule structures. These pockets could accommodate the same residues of one peptide in similar manners ([@B4]).

We identified the MHC restriction of five CTL epitopes. CD8+ T cell epitopes are known to be strictly restricted to SLA class I molecules, suggesting that identification of MHC-I-restricted CTL epitopes could aid the rational development and modification of peptide-based vaccines. Current vaccines are usually ineffective against newly emerged virus strains because of the rapid mutation of viral proteins through both antigenic drift and shift, for example influenza virus. New vaccines therefore need to be developed against their mutant virus, and new-vaccine strategies increasingly are directed at conserved viral CTL epitope-based vaccines. Few polypeptide vaccines have been utilized in swine to date because of the MHC restriction of peptides and the high polymorphism of SLA class I genes. In this study, we constructed SLA class I complexes consisting of viral epitope peptides, the extracellular region of SLA-1 molecules, and β2m, and expressed and refolded them *in vitro*, and used an ELISA-based method to determine the MHC restriction of five CTL epitopes. It is hoped to develop the more effective polypeptide vaccines for these CTL epitope peptides. Many T-cell epitopes derived from various swine-origin viruses have been identified using *in vivo* cytotoxicity assays, enzyme-linked immunospot assays, intracellular cytokine staining, flow cytometry, and so on ([@B28]; [@B10]; [@B39]; [@B3]; [@B40]; [@B43]; [@B1]), but most of these methods are relatively labor intensive and technically demanding, and importantly do not clarify the MHC restriction of the epitopes. Gao et al. reconstructed a SLA-2-(G4S)3-b2m protein complex *in vitro*, which could be used to identify nonameric viral peptides in swine, in conjunction with mass spectrometry ([@B8]). Similarly, the current study presented a method for not only generating recombinant SLA-1 molecules and mapping their specificities, but also for identifying nonameric MHC-I-restricted epitopes. This method could avoid the one-sidedness of predicting epitopes only depending on protein sequences and thus improve the accuracy of epitope identification.

In addition, we analyzed the amino acid sequence homologies of the α1 and α2 domains among seven SLA-1 molecules. The SLA-1^∗^04:01:01 and SLA-1^∗^13:01 had 97.1% homology, implying that they might bind the same classes of peptide. However, these proteins showed distinctly different epitope-binding specificities. We examined the basis for these different binding specificities by alignment of the amino acid residues of the PBG and observed eight discrepant amino acid residues, of which four \[66(N/K), 70(T/N), 99(Y/F), 152(E/V)\] were involved in the formation of pockets B, C, D, and E, respectively. We mutated each of the four different amino acid residues of one molecule to the corresponding residues of the other molecule and determined the effect of the mutations on the specific binding of the CSFV NS4A epitope peptide. The NS4A epitope peptide could not bind to the SLA-1^∗^13:01/152 mutant protein when Val^152^ alone was mutated, and could not bind to the SLA-1^∗^04:01:01/152 mutant protein. We obtained similar results for the Asn^151^ residue. However, when the 151(D/N) and 152(E/V) residues of SLA-1^∗^13:01 and SLA-1^∗^04:01:01 were mutated simultaneously to those of the corresponding molecule, the five epitope peptides could not bind to the SLA-1^∗^13:01/151/152 mutant protein, but could bind to the SLA-1^∗^04:01:01/151/152 mutant protein. Moreover, the relative level of epitope peptides binding to SLA-1^∗^04:01:01/151/152 mutant was obviously increased, indicating the binding strength of peptides to SLA-1^∗^04:01:01 was enhanced when simultaneously mutating 151 and 152 amino acid residues. In turn, the binding strength of SLA-1^∗^13:01/151/152 mutant to epitope peptides were nearly identical to SLA-1^∗^04:01:01, indicating the weak binding strength. This suggests that the fixed combination of Asn^151^Val^152^ residues might be the key residues influencing the binding of viral CTL epitope peptides to SLA-1^∗^13:01 and SLA-1^∗^04:01:01 proteins. The crystal structure of SLA-1^∗^04:01:01 revealed that Arg^156^ in pocket D had a 'one-ballot veto' function in peptide binding, due to its flexible side chain ([@B42]). However, the different epitope peptide conformations are caused not only by the flexibility of the side chains of the residues in the PBG, but also by skewing of the α1 and α2 helixes forming the PBG ([@B4]). Thus although the Asn^151^ residue of SLA-1^∗^13:01 did not constitute part of the pockets of the PBG, it occurred in turn and random coil content and thus increased the flexibility support of pocket E, which may result in skewing of the α helixes forming the PBG. Furthermore, pocket E of SLA-1^∗^13:01 was larger than that of SLA-1^∗^04:01:01 as a result of the different surfaces of the concave Val^152^ and salient Glu^152^ residues, suggesting that pocket E in the SLA-1^∗^13:01 protein might have fewer steric limitations and be able to accommodate more viral CTL epitope peptides. The flexible pocket E of SLA-1^∗^04:01:01/151/152 might also adopt various conformations to accommodate the peptides through mutation of the Asp^151^ and Glu^152^ residues, leading to distinct peptide conformations, and might thus play critical biochemical roles in determining the peptide-binding motif of SLA-1^∗^13:01. A strong correlation exists between high-affinity SLA-I binding peptides and the stability of the complexes, with high-affinity SLA-I binding peptides generally forming more stable complexes ([@B31]). Changes in several amino acid residues of SLA class I molecules could thus influence the affinity and stability of complexes, thereby affecting the peptide-binding specificity of SLA class I molecules. Furthermore, the binding specificity also could be affected by changes in amino acid polarity. Interestingly, in contrast to a previous study ([@B27]), we found that the CSFV NS4A epitope peptide could not bind to SLA-1^∗^04:01:01 but could bind to SLA-1^∗^13:01, with relative OD values of up to 4.7. However, the NS4A epitope peptide could bind to the SLA-1^∗^04:01:01/151/152 mutant protein when both the Asp^151^ and Glu^152^ residues were mutated simultaneously. This discrepancy may be because the *in vitro* refolding method for the protein complexes in the current study differed from that used in the previous study, and the binding specificity of the H4 w/o protein with synthetic (free) NS4A peptide was also not observed in the refold reactions ([@B27]). Further work is therefore needed to determine the crystal structure of the NS4A peptide-SLA-1^∗^04:01:01 complex to thoroughly explore this phenomenon. Certainly, it is beneficial if the promiscuity of SLA-1^∗^13:01 and SLA-1^∗^04:01:01 were investigated in terms of the peptide binding affinity and the stability of the complexes. Therefore, our future study will focused on the peptide binding affinity and stability to SLA class I molecules and stability of the SLA complex by using various methods, for example, luminescent oxygen channeling assay and scintillation proximity assay-based peptide-SLA dissociation. Furthermore, we also will attempt to perform molecular dynamics simulations to investigate the binding difference of SLA class I molecular to epitope peptides by using various software, for example, Discovery Studio and CHARMM.

Conclusion
==========

We successfully constructed SLA class I complexes consisting of viral epitope peptides, the extracellular region of SLA-1 molecules, and β2m *in vitro*. We also detected the specific binding of seven SLA-1 proteins to five viral CTL epitope peptides through the expression and refolding of the protein complexes. The SLA-1^∗^13:01, SLA-1^∗^11:10, and SLA-1^∗^11:01:02 proteins were able to specifically bind different CTL epitopes of CSFV and PRRSV, and the MHC restrictions of five epitopes were identified. Moreover, the fixed combination of Asn^151^Val^152^ residues might represent the key residues influencing the binding of viral several CTL epitope peptides to SLA-1^∗^13:01 and SLA-1^∗^04:01:01. The increased flexibility of pocket E in the SLA-1^∗^13:01 protein might play a critical biochemical role in determining the peptide-binding motif of SLA-1^∗^13:01. Characterization of the peptide-specific binding properties of SLA class I molecules provides essential information for the future identification of novel epitopes, as well as for the overall validation and analysis of currently available or newly developed CTL-based vaccines in swine. This information may also lead to improved understanding of the structural basis of CTL-based immune responses.
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